AITRICS, the Seoul-based medical AI powerhouse, just closed a $24 million Series C round in late November 2025, pushing its total funding to $50 million.
Nine venture capital firms backed the round, led by Premier Partners, Hanriver Partners, and Mirae Asset Venture Investment, with new investors including KB Securities-Solidus Investment and SV Investment joining the cap structure.
What Makes AITRICS the AI Copilot Hospitals Actually Use?
Founded in 2017 by Dr. Kwang Joon Kimâa geriatrician and endocrinologist at Yonsei UniversityâAITRICS builds predictive AI that stops patient deterioration before it becomes critical.
Its flagship product, AITRICS-VC (VitalCare), analyzes 19 data points from electronic medical records to predict sepsis, cardiac arrest, and death hours earlier than traditional monitoring. The company also offers V.Doc Pro, an AI copilot that assists clinicians with real-time decision support.
AITRICS isn't just lab-tested theory. VitalCare is deployed in over 40 hospitals across South Korea, including Gangnam Severance Hospital and Asan Medical Center. The company secured Korean FDA approval in 2022 and has been pushing hard for U.S. FDA clearance to unlock the North American market.
AITRICS Funding Snapshot
| Round | Amount | Year | Key Investors |
|---|---|---|---|
| Seed/Series A | $5.1M | 2017-2019 | Early backers |
| Pre-Series B | $2.4M | 2021 | Follow-on investors |
| Series B | $18.5M | 2024 | Premier Partners, BNH Investment, BSK Investment |
| Series C | $24M | 2025 | Premier Partners, Hanriver Partners, Mirae Asset, KB Securities |
| Total Raised | $50M |
â AICurator Rating: 8.5/10
Why This Round Screams Market Validation?
This Series C came barely 18 months after AITRICS raised $18.5 million in Series B. The rapid follow-on signals strong investor confidence in the healthtech AI sector, especially for clinical decision support tools.
SV Investment noted they invested because of “AITRICS's innovative AI solutions, outstanding clinical results, and clear business strategy”. The capital will supercharge product development for both VitalCare and V.Doc Pro, fund new R&D pipelines, and fuel aggressive geographic expansion into Vietnam, Hong Kong, and North America.
AITRICS already established a U.S. subsidiary in December 2023 and is collaborating with Mayo Clinic Platform to validate AI models using U.S. clinical data.
Connect with AITRICS
| Platform | Link |
|---|---|
| Website | aitrics.com |
| linkedin.com/company/aitrics | |
| CEO LinkedIn | linkedin.com/in/kwang-joon-kim |
